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978CRP. Finally, we note that CRP—an acute-phase pro-
tein produced by the liver—is reported to have
declined from the coronary sinus efﬂuent within
1 h, which is inconsistent with the reported half-life
of CRP of w19 h (5).Asif Machhada, BSc
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Atrial FibrillationWe thank Dr. Machhada and colleagues for their
insightful comments regarding the effects of low-
level tragus stimulation (LLTS) on C-reactive protein
(CRP). Although the CRP levels appear to be non-
normally distributed in the LLTS group, the assump-
tions of constant variance and normality were
reasonable for this model on the basis of the residual
plots, as pointed out in the statistical methods of
our paper (1). In addition, in our statistical model we
did control for baseline CRP levels. The ﬁnal results
thus reﬂect the effect of LLTS after adjustment for
baseline CRP levels.
Atrial ﬁbrillation is characterized by systemic
inﬂammation, which is supported by the elevatedlevels of inﬂammatory cytokines, including tumor
necrosis factor (TNF)-a and CRP, in our patient
population (1). Importantly, the magnitude of
decrease in inﬂammatory cytokine levels by LLTS is
consistent with the difference between controls and
pre–rheumatoid arthritis patients (1). This effect is
unlikely the result of anesthesia or body mass
index, both of which have been shown to affect
CRP levels (2), given that the exposure of the con-
trol and experimental groups to each of these fac-
tors was balanced between the 2 groups. We cannot
comment on the exact time course of CRP in our
study, as we did not obtain serial measurements of
CRP. The plasma half-life of CRP was determined
in ambulatory healthy volunteers (3). It is unknown
whether anesthesia affects the plasma half-life of
CRP. However, a recent study showed that anes-
thesia signiﬁcantly decreased CRP transiently 30 min
post-operatively compared with pre-operative levels
(2). It should be noted that the anti-inﬂammatory
effect of LLTS on TNF-a is consistent with its half-
life of approximately 18 min (4). In addition, other
studies have shown a signiﬁcant decrease in TNF-a
after just 20 min of vagus nerve stimulation (5).
In summary, the overall results of our study sup-
port the notion that vagal stimulation modulates
inﬂammation.Stavros Stavrakis, MD, PhD
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